Bruker Corporation announces the appointment of Mr. Thierry L. Bernard to serve on its Board of Directors, effective as of April 1, 2026. Mr. Bernard is an international life-science tools and diagnostics industry executive with decades of relevant leadership, strategic and operational experience. Mr. Bernard currently serves as Chief Executive Officer of QIAGEN N.V. He joined QIAGEN in 2015 to lead its growing molecular diagnostics business and was named Chief Executive Officer in 2019.
He has announced his intention to step down as CEO upon the appointment of a successor. Previously, Mr. Bernard held roles of increasing responsibility during 15 years with bioMérieux SA, including as Corporate Vice President for Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in several other leading international companies.
In 2023, Mr. Bernard was named Chair of the Board of Directors of the U.S. trade industry association AdvaMedDx and joined the Board of Directors of Neogen Corporation in 2024. He has earned degrees and certifications from Sciences Po Paris, the London School of Economics, the College of Europe, Harvard Business School and Centro de Comercio Exterior de Barcelona.
